I.P. Melko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
I.P. Melko has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- O. I. Dorosh
Danylo Halytsky Lviv National Medical University, Ukraine; NPE LRC Clinical Center of Pediatrics, SP Specialized Center, Lviv, Ukraine
8 shared publications - O.A. Petronchak
ТзОВ «Західноукраїнська гістологічна лабораторія», м. Львів
5 shared publications - A. A. Seleznov
Pathomorphological Laboratory CSD, Kyiv
4 shared publications - A.M. Mykh
КНП Львівської обласної ради «Клінічний центр дитячої медицини», СП «Західноукраїнський спеціалізований центр
4 shared publications - Bohdan Romanyshyn
КНП Львівської обласної ради «Клінічний центр дитячої медицини», СП «Західноукраїнський спеціалізований центр
3 shared publications - I.P. Tsymbalyuk-Voloshyn3 shared publications
Latest Publications
- Open Access
- 28 May 2024
- Published by Group of Companies Med Expert, LLC in Modern pediatrics. Ukraine
- No. 4(140),p. 97-112
Ulcerative colitis, hereditary spherocytosis and haemochromatosis in a child: an integrated approach to clinical case management
Inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), is a chronic systemic idiopathic pathology of the intestinal tract with extraintestinal manifestations (EIM) in some patients. One of the most common complications in these patients is anemia, which can be the result of iron, vitamin B12 or B9 deficiency; intestinal absorption disorders or autoimmune hemolysis. Aim - to describe a rare clinical case of a 10-year and 10-month-old boy diagnosed with UC and EIM, hereditary spherocytosis (HS) caused by a heterozygous ANK1 gene-mutation and hereditary hemochromatosis associated with a pathogenic HFE gene- mutation. This case underscores the importance of genetic testing, pathological examinations, and accurate interpretation of peripheral blood smear morphology for disease diagnosis. Clinical case. We present a unique combination of UC with EIM, НS caused by a pathogenic heterozygous mutation in the ANK1 gene (exon c.2394_2397del (p.Ser799Ilefs*5)), and hereditary hemochromatosis with a heterozygous pathogenic mutation in the HFE gene (exon c.187C>G (p.His63Asp) in a boy aged 10 years 10 months. The child was abdominal and right hip pain, abdominal enlargement. Diagnosis of HS and hemochromatosis was confirmed through whole-genome sequencing and pathological examination of the spleen. UC with EIM (by Pediatric Ulcerative Colitis Activity Index - 15 points) diagnosed based on clinical presentation, colonoscopy, laboratory tests (elevated IgG antibodies to proteinase 3 and inflammatory changes in the blood). This case emphasizes the crucial role of molecular genetic testing and careful analysis of peripheral blood smears by cytologists in the accurate diagnosis of complex diseases. The research was carried out in accordance with the principles of the Helsinki Declaration. The informed consent of the patient was obtained for conducting the studies. No conflict of interests was declared by the authors.
- 28 May 2024
- Published by Group of Companies Med Expert, LLC in Modern pediatrics. Ukraine
- No. 4(140),p. 97-112
Open AccessUlcerative colitis, hereditary spherocytosis and haemochromatosis in a child: an integrated approach to clinical case management
Inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), is a chronic systemic idiopathic pathology of the intestinal tract with extraintestinal manifestations (EIM) in some patients. One of the most common complications in these patients is anemia, which can be the result of iron, vitamin B12 or B9 deficiency; intestinal absorption disorders or autoimmune hemolysis. Aim - to describe a rare clinical case of a 10-year and 10-month-old boy diagnosed with UC and EIM, hereditary spherocytosis (HS) caused by a heterozygous ANK1 gene-mutation and hereditary hemochromatosis associated with a pathogenic HFE gene- mutation. This case underscores the importance of genetic testing, pathological examinations, and accurate interpretation of peripheral blood smear morphology for disease diagnosis. Clinical case. We present a unique combination of UC with EIM, НS caused by a pathogenic heterozygous mutation in the ANK1 gene (exon c.2394_2397del (p.Ser799Ilefs*5)), and hereditary hemochromatosis with a heterozygous pathogenic mutation in the HFE gene (exon c.187C>G (p.His63Asp) in a boy aged 10 years 10 months. The child was abdominal and right hip pain, abdominal enlargement. Diagnosis of HS and hemochromatosis was confirmed through whole-genome sequencing and pathological examination of the spleen. UC with EIM (by Pediatric Ulcerative Colitis Activity Index - 15 points) diagnosed based on clinical presentation, colonoscopy, laboratory tests (elevated IgG antibodies to proteinase 3 and inflammatory changes in the blood). This case emphasizes the crucial role of molecular genetic testing and careful analysis of peripheral blood smears by cytologists in the accurate diagnosis of complex diseases. The research was carried out in accordance with the principles of the Helsinki Declaration. The informed consent of the patient was obtained for conducting the studies. No conflict of interests was declared by the authors.
- Open Access
- 28 October 2023
- Published by Group of Companies Med Expert, LLC in Modern pediatrics. Ukraine
- No. 6(134),p. 133-141
Genetic verification of an autoinflammatory syndrome caused by a heterozygous mutation in the SOCS1 gene masquerading as hemoblastosis. Clinical case
Familial autoinflammatory syndrome with or without immunodeficiency (AISIMD), caused by a heterozygous mutation in the SOCS1 gene on chromosome 16p13, is characterized by the appearance of various autoimmune signs usually in the first decades of life, although later onset has been reported. Typical features of AISIMD include autoimmune cytopenia, thrombocytopenia, hemolytic anemia and lymphadenopathy, possible alterations in cellular immunity, and hypogammaglobulinemia. Purpose - to present a combination of clinical, imaging and laboratory signs in a nine-year-old patient with autoinflammatory syndrome and mild immunodeficiency caused by a heterozygous mutation in the SOCS1 gene; to emphasise the importance of genetic tests for definitive diagnosis. Clinical case. Features of diagnosis of autoinflammatory syndrome caused by heterozygous mutation in the SOCS1 gene in a 9-year-old boy are described. The disease was manifested in the laboratory by leukopenia with neutropenia, monocytosis, thrombocytopenia, an increase in markers of inflammation - C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), impaired cellular immunity (inverse CD4/CD8 ratio, reduced number of NK cells (CD3-CD16+CD56+), decrease in CD19, increase in the per cent of double-negative T-lymphocytes (Neg. In T- Double LF (CD3+CD4-CD8-); clinical: hyperthermia, recurrent aphthous stomatitis, irritable bowel syndrome, progressive generalized lymphoproliferative syndrome. Differential diagnosis with hemoblastosis was carried out, which was denied. Subsequently the presence of an ulcer in the ileum and mucinous metaplasia in the covering epithelium gave grounds to diagnose an inflammatory bowel disease: Crohn's disease with damage to the terminal part of the small intestine. Verification of the final diagnosis of an autoinflammatory syndrome caused by a heterozygous mutation in the SOCS1 gene took place using genome sequencing. The research was carried out in accordance with the principles of the Helsinki Declaration. The informed consent of the patient was obtained for conducting the studies. No conflict of interests was declared by the authors.
- 28 October 2023
- Published by Group of Companies Med Expert, LLC in Modern pediatrics. Ukraine
- No. 6(134),p. 133-141
Open AccessGenetic verification of an autoinflammatory syndrome caused by a heterozygous mutation in the SOCS1 gene masquerading as hemoblastosis. Clinical case
Familial autoinflammatory syndrome with or without immunodeficiency (AISIMD), caused by a heterozygous mutation in the SOCS1 gene on chromosome 16p13, is characterized by the appearance of various autoimmune signs usually in the first decades of life, although later onset has been reported. Typical features of AISIMD include autoimmune cytopenia, thrombocytopenia, hemolytic anemia and lymphadenopathy, possible alterations in cellular immunity, and hypogammaglobulinemia. Purpose - to present a combination of clinical, imaging and laboratory signs in a nine-year-old patient with autoinflammatory syndrome and mild immunodeficiency caused by a heterozygous mutation in the SOCS1 gene; to emphasise the importance of genetic tests for definitive diagnosis. Clinical case. Features of diagnosis of autoinflammatory syndrome caused by heterozygous mutation in the SOCS1 gene in a 9-year-old boy are described. The disease was manifested in the laboratory by leukopenia with neutropenia, monocytosis, thrombocytopenia, an increase in markers of inflammation - C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), impaired cellular immunity (inverse CD4/CD8 ratio, reduced number of NK cells (CD3-CD16+CD56+), decrease in CD19, increase in the per cent of double-negative T-lymphocytes (Neg. In T- Double LF (CD3+CD4-CD8-); clinical: hyperthermia, recurrent aphthous stomatitis, irritable bowel syndrome, progressive generalized lymphoproliferative syndrome. Differential diagnosis with hemoblastosis was carried out, which was denied. Subsequently the presence of an ulcer in the ileum and mucinous metaplasia in the covering epithelium gave grounds to diagnose an inflammatory bowel disease: Crohn's disease with damage to the terminal part of the small intestine. Verification of the final diagnosis of an autoinflammatory syndrome caused by a heterozygous mutation in the SOCS1 gene took place using genome sequencing. The research was carried out in accordance with the principles of the Helsinki Declaration. The informed consent of the patient was obtained for conducting the studies. No conflict of interests was declared by the authors.
- 29 October 2021
- Published by Group of Companies Med Expert, LLC in Modern pediatrics. Ukraine
- No. 6(118),p. 44-54
Successful treatment of pulmonary tuberculosis in a child with acute promyelocytic leukemia, on the background of intensive chemotherapy
The predisposition of patients with acute leukemia (АL) to various infectious complications is a well-known fact. The reason is a decrease in immunity due to the underlying disease and due to the use of immunosuppressive cytostatic and radiotherapy. Tuberculosis infections (TIs) are serious and life-threatening complications in patients with malignant hematological disorders and recipients after hematopoietic stem cell transplantation. Verification of tuberculosis (TB) is often delayed among patients with hematooncological diseases due to low suspicion and due to the search for other infectious complications. Those with the involvement of the respiratory system are the most common complications in immunologically compromised patients. In acute leukemia, the TB process may have been underestimated, due to negative tests for mycobacterium tuberculosis (MBT), and patients with neoplasia are often prescribed antibacterial agents such as amikacin and ftorchinolones, which are also effective against TI. We describe a 10-year-old boy who was diagnosed with pulmonary tuberculosis, a disseminated form complicated by hydrothorax, during induction chemotherapy for acute promyelocytic leukemia (APL). For diagnostic purposes, repeated punctures of the pleural cavity with drainage of pathological effusion and diagnostic and remedial bronchoscopy were performed, bacterial pneumonia and systemic mycosis were suspected. The diagnosis of TB was verified on the basis of positive PCR test for TB, molecular genetic study of sputum, bronchial lavage for the presence of genome of MBT without resistance to rifampicin, sputum microscopy, while sputum culture and pleural fluid were negative for MBT. TB treatment was coEadministered with AML-BFM 2004 intensive cytostatic therapy without dose reduction of cytostatics. The child was prescribed intensive tuberculostatic therapy with 4 drugs (rifampicin + isoniazid + pyrazinamide + inbutol) for 3 months and subsequent maintenance antituberculous chemotherapy with two drugs for 4 months (rifampicin + isonimazide). With this analysis, we advocate the need for early suspicion of TB in patients receiving treatment for AL. The results of our study suggest that antitumor chemotherapy is not an obstacle to effective TB-treatment. The described patient is in remission of AML and TB for 21 months. The research was carried out in accordance with the principles of the Helsinki declaration. The informed consent of the patient was obtained for conducting the studies. No conflict of interest was declared by the authors. Key words: acute promyelocytic leukemia, tuberculosis, cytostatic therapy, children.
- 29 October 2021
- Published by Group of Companies Med Expert, LLC in Modern pediatrics. Ukraine
- No. 6(118),p. 44-54
Successful treatment of pulmonary tuberculosis in a child with acute promyelocytic leukemia, on the background of intensive chemotherapy
The predisposition of patients with acute leukemia (АL) to various infectious complications is a well-known fact. The reason is a decrease in immunity due to the underlying disease and due to the use of immunosuppressive cytostatic and radiotherapy. Tuberculosis infections (TIs) are serious and life-threatening complications in patients with malignant hematological disorders and recipients after hematopoietic stem cell transplantation. Verification of tuberculosis (TB) is often delayed among patients with hematooncological diseases due to low suspicion and due to the search for other infectious complications. Those with the involvement of the respiratory system are the most common complications in immunologically compromised patients. In acute leukemia, the TB process may have been underestimated, due to negative tests for mycobacterium tuberculosis (MBT), and patients with neoplasia are often prescribed antibacterial agents such as amikacin and ftorchinolones, which are also effective against TI. We describe a 10-year-old boy who was diagnosed with pulmonary tuberculosis, a disseminated form complicated by hydrothorax, during induction chemotherapy for acute promyelocytic leukemia (APL). For diagnostic purposes, repeated punctures of the pleural cavity with drainage of pathological effusion and diagnostic and remedial bronchoscopy were performed, bacterial pneumonia and systemic mycosis were suspected. The diagnosis of TB was verified on the basis of positive PCR test for TB, molecular genetic study of sputum, bronchial lavage for the presence of genome of MBT without resistance to rifampicin, sputum microscopy, while sputum culture and pleural fluid were negative for MBT. TB treatment was coEadministered with AML-BFM 2004 intensive cytostatic therapy without dose reduction of cytostatics. The child was prescribed intensive tuberculostatic therapy with 4 drugs (rifampicin + isoniazid + pyrazinamide + inbutol) for 3 months and subsequent maintenance antituberculous chemotherapy with two drugs for 4 months (rifampicin + isonimazide). With this analysis, we advocate the need for early suspicion of TB in patients receiving treatment for AL. The results of our study suggest that antitumor chemotherapy is not an obstacle to effective TB-treatment. The described patient is in remission of AML and TB for 21 months. The research was carried out in accordance with the principles of the Helsinki declaration. The informed consent of the patient was obtained for conducting the studies. No conflict of interest was declared by the authors. Key words: acute promyelocytic leukemia, tuberculosis, cytostatic therapy, children.
- 25 May 2020
- Published by Group of Companies Med Expert, LLC in Modern pediatrics. Ukraine
- No. 3(107),p. 77-86
Parvovirus B19-viremia. Clinical and laboratory presentation
- 25 May 2020
- Published by Group of Companies Med Expert, LLC in Modern pediatrics. Ukraine
- No. 3(107),p. 77-86
Parvovirus B19-viremia. Clinical and laboratory presentation
- 30 December 2019
- Published by Group of Companies Med Expert, LLC in Modern pediatrics. Ukraine
- No. 8(104),p. 71-82
Kikuchi–Fujimoto disease: features of diagnosis and clinical course
- 30 December 2019
- Published by Group of Companies Med Expert, LLC in Modern pediatrics. Ukraine
- No. 8(104),p. 71-82
Kikuchi–Fujimoto disease: features of diagnosis and clinical course
- 30 September 2019
- Published by Group of Companies Med Expert, LLC in Modern pediatrics. Ukraine
- No. 5(101),p. 9-30
Leukemoid reactions and chronic chronic myeloproliferative diseases in children: similarity and differences
- 30 September 2019
- Published by Group of Companies Med Expert, LLC in Modern pediatrics. Ukraine
- No. 5(101),p. 9-30
Leukemoid reactions and chronic chronic myeloproliferative diseases in children: similarity and differences
- 30 November 2018
- Published by Group of Companies Med Expert, LLC in SOVREMENNAYA PEDIATRIYA
- No. 7(95),p. 51-58
Gorham—Stout disease of the thoracic and lumbar spine, ribs and with bilateral hydrothorax in a 11-year-old boy. Сlinical case
- 30 November 2018
- Published by Group of Companies Med Expert, LLC in SOVREMENNAYA PEDIATRIYA
- No. 7(95),p. 51-58
Gorham—Stout disease of the thoracic and lumbar spine, ribs and with bilateral hydrothorax in a 11-year-old boy. Сlinical case
- 29 April 2018
- Published by Group of Companies Med Expert, LLC in SOVREMENNAYA PEDIATRIYA
- No. 3(91),p. 74-85
Secondary CNS tumours in children initially treated from ALL according to the treatment protocols of chemotherapy and radiotherapy
- 29 April 2018
- Published by Group of Companies Med Expert, LLC in SOVREMENNAYA PEDIATRIYA
- No. 3(91),p. 74-85
Secondary CNS tumours in children initially treated from ALL according to the treatment protocols of chemotherapy and radiotherapy